​

HUTCHMED (China) (HCM) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

HUTCHMED (China) Revenue Highlights

Latest Revenue (Y)

$838.00M

Latest Revenue (Q)

$152.84M

Main Segment (Y)

Other Collaboration Licensing Revenue

HUTCHMED (China) Revenue by Period

HUTCHMED (China) Revenue by Year

DateRevenueChange
2023-12-31$838.00M96.52%
2022-12-31$426.41M19.73%
2021-12-31$356.13M56.21%
2020-12-31$227.98M11.27%
2019-12-31$204.89M-4.31%
2018-12-31$214.11M-11.23%
2017-12-31$241.20M11.63%
2016-12-31$216.08M21.25%
2015-12-31$178.20M94.09%
2014-12-31$91.81M99.72%
2013-12-31$45.97M-76.47%
2012-12-31$195.39M17.05%
2011-12-31$166.92M24.10%
2010-12-31$134.51M21.18%
2009-12-31$111.00M-

HUTCHMED (China) generated $838.00M in revenue during NA 2023, up 96.52% compared to the previous quarter, and up 391.39% compared to the same period a year ago.

HUTCHMED (China) Revenue by Quarter

DateRevenueChange
2024-06-30$152.84M-
2024-03-31$152.84M0.18%
2023-12-31$152.56M-
2023-09-30$152.56M-42.74%
2023-06-30$266.44M-
2023-03-31$266.44M137.51%
2022-12-31$112.18M-
2022-09-30$112.18M-44.48%
2022-06-30$202.05M100.00%
2022-03-31$101.02M-26.88%
2021-12-31$138.16M39.02%
2021-09-30$99.38M31.10%
2021-06-30$75.81M-7.05%
2021-03-31$81.56M34.57%
2020-12-31$60.61M-
2020-09-30$60.61M9.80%
2020-06-30$55.20M7.03%
2020-03-31$51.57M-2.41%
2019-12-31$52.84M7.08%
2019-09-30$49.35M-1.36%
2019-06-30$50.03M-4.10%
2019-03-31$52.17M-55.05%
2018-12-31$116.05M97.33%
2018-09-30$58.81M17.97%
2018-06-30$49.85M-4.75%
2018-03-31$52.34M-53.54%
2017-12-31$112.66M96.58%
2017-09-30$57.31M-54.73%
2017-06-30$126.58M100.00%
2017-03-31$63.29M13.46%
2016-12-31$55.78M-
2016-09-30$55.78M6.74%
2016-06-30$52.26M-
2016-03-31$52.26M-7.15%
2015-12-31$56.28M0.15%
2015-09-30$56.20M36.26%
2015-06-30$41.24M-
2015-03-31$41.24M22.90%
2014-12-31$33.56M20.18%
2014-09-30$27.93M84.15%
2014-06-30$15.16M-
2014-03-31$15.16M216.88%
2013-12-31$4.79M-66.32%
2013-09-30$14.21M61.89%
2013-06-30$8.78M-
2013-03-31$8.78M43.29%
2012-12-31$6.13M-
2012-09-30$6.13M-

HUTCHMED (China) generated $152.84M in revenue during Q2 2024, up 0.00% compared to the previous quarter, and up 57.36% compared to the same period a year ago.

HUTCHMED (China) Revenue Breakdown

HUTCHMED (China) Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Other Collaboration Royalties Revenue$32.47M$26.31M$15.06M$4.89M$2.65M
Research And Development Services$481.00K$507.00K$525.00K$491.00K$494.00K
Other Collaboration Licensing Revenue$278.86M$14.95M$23.66M--
Commercialization Services$48.61M$41.27M$27.43M$3.73M$2.58M
Collaboration Research And Development$80.40M$23.74M$19.00M$9.77M$15.53M
Goods-$314.33M$266.20M--
Product---$203.61M$175.99M

HUTCHMED (China)'s latest annual revenue breakdown by segment (product or service), as of Dec 23: Other Collaboration Licensing Revenue (63.26%), Collaboration Research And Development (18.24%), Commercialization Services (11.03%), Other Collaboration Royalties Revenue (7.37%), and Research And Development Services (0.11%).

Quarterly Revenue by Product

Product/ServiceDec 23Jun 23Jun 22Jun 21Jun 20Dec 19
Research And Development Services$235.00K$246.00K$263.00K$261.00K$240.00K$121.00K
Collaboration Research And Development$51.68M$28.72M$12.34M$4.79M$7.51M$5.06M
Commercialization Services$23.25M$25.36M$21.59M$15.03M--
Other Collaboration Licensing Revenue$28.79M$250.07M$14.95M---
Other Collaboration Royalties Revenue$17.49M$14.98M$14.33M$5.82M$2.04M$91.00K
Seroquel-$1.10M----
Product--$136.93M$129.15M$94.89M$45.77M

HUTCHMED (China)'s latest quarterly revenue breakdown by segment (product or service), as of Dec 23: Collaboration Research And Development (42.56%), Other Collaboration Licensing Revenue (23.70%), Commercialization Services (19.15%), Other Collaboration Royalties Revenue (14.40%), and Research And Development Services (0.19%).

HUTCHMED (China) Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ALKSAlkermes$1.66B$378.14M
PBHPrestige Consumer Healthcare$1.13B$283.55M
PAHCPhibro Animal Health$977.89M$273.16M
HCMHUTCHMED (China)$838.00M$152.84M
PCRXPacira BioSciences$674.98M$168.57M
COLLCollegium Pharmaceutical$566.77M$159.30M
ANIPANI Pharmaceuticals$486.82M$148.33M
ITCIIntra-Cellular Therapies$462.18M$175.38M
IRWDIronwood Pharmaceuticals$442.74M$91.59M
PROCProcaps Group$409.92M$118.41M
RGCRegencell Bioscience--

HCM Revenue FAQ

What is HUTCHMED (China)’s yearly revenue?

HUTCHMED (China)'s yearly revenue for 2023 was $838M, representing an increase of 96.52% compared to 2022. The company's yearly revenue for 2022 was $426.41M, representing an increase of 19.73% compared to 2021. HCM's yearly revenue for 2021 was $356.13M, representing an increase of 56.21% compared to 2020.

What is HUTCHMED (China)’s quarterly revenue?

HUTCHMED (China)'s quarterly revenue for Q2 2024 was $152.84M, a 0% increase from the previous quarter (Q1 2024), and a -42.64% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $152.84M, a 0.18% increase from the previous quarter (Q4 2023), and a -42.64% decrease year-over-year (Q1 2023). HCM's quarterly revenue for Q4 2023 was $152.56M, a 0% increase from the previous quarter (Q3 2023), and a 36.00% increase year-over-year (Q4 2022).

What is HUTCHMED (China)’s revenue growth rate?

HUTCHMED (China)'s revenue growth rate for the last 3 years (2021-2023) was 135.31%, and for the last 5 years (2019-2023) was 309.00%.

What are HUTCHMED (China)’s revenue streams?

HUTCHMED (China)'s revenue streams in c 23 are Other Collaboration Royalties Revenue, Research And Development Services, Other Collaboration Licensing Revenue, Commercialization Services, and Collaboration Research And Development. Other Collaboration Royalties Revenue generated $32.47M in revenue, accounting 7.37% of the company's total revenue, up 23.41% year-over-year. Research And Development Services generated $481K in revenue, accounting 0.11% of the company's total revenue, down -5.13% year-over-year. Other Collaboration Licensing Revenue generated $278.86M in revenue, accounting 63.26% of the company's total revenue, up 1764.75% year-over-year. Commercialization Services generated $48.61M in revenue, accounting 11.03% of the company's total revenue, up 17.77% year-over-year. Collaboration Research And Development generated $80.4M in revenue, accounting 18.24% of the company's total revenue, up 238.64% year-over-year.

What is HUTCHMED (China)’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of HUTCHMED (China) was Other Collaboration Licensing Revenue. This segment made a revenue of $278.86M, representing 63.26% of the company's total revenue.